Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization

References

• Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc. 2010;85(3):225-30
   Google Scholar
• Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23:9219-26
   PubMed Web of Science ®Google Scholar
• Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015;100:107-13
   PubMed Web of Science ®Google Scholar
• Teh BW, Harrison SJ, Pellegrini M, et al. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. Blood Rev 2014;28:75-86
   PubMed Web of Science ®Google Scholar
• Teh BW, Harrison SJ, Worth LJ, et al. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Fulop T, Larbi A, Pawelec G. Human T cell aging and the impact of persistent viral infections. Front Immunol 2013;4:271
   Google Scholar
• James SH, Prichard MN. Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance. Curr Opin Virol 2014;8:54-61
   Web of Science ®Google Scholar
• Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014;20:6262-78
   PubMed Web of Science ®Google Scholar
• Boeckh M, Murphy WJ, Peggs KS. Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant 2015;21:24-9
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006;85:278-87
   PubMed Web of Science ®Google Scholar
• Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004;39:1300-6
   PubMed Web of Science ®Google Scholar
• Truong Q, Veltri L, Kanate AS, et al. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients. Ann Hematol 2014;93:677-82
   PubMed Web of Science ®Google Scholar
• Teh BW, Worth L.J, Harrison SJ, et al. The timing and clinical predictors of herpesvirus infections in patients with myeloma in the setting of antiviral prophylaxis. 25th European Congress for Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark, 2015
   Google Scholar
• Konig C, Kleber M, Reinhardt H, et al. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol 2014;93:479-84
   PubMed Web of Science ®Google Scholar
• Teh BW, Worth LJ, Harrison SJ, et al. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. Support Care Cancer 2015;23:1901-6
   PubMed Web of Science ®Google Scholar
• Schütt P, Brandhorst D, Stellberg W, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006;47:1570-82
   PubMed Web of Science ®Google Scholar
• Teh BW, Khot AS, Harrison SJ, et al. A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease. Transpl Infect Dis 2013;15:E134-8
   PubMed Web of Science ®Google Scholar
• Li J, Li Y, Huang B, et al. Drug-induced modulation of T lymphocytes as a potential mechanism of susceptibility to infections in patients with multiple myeloma during bortezomib therapy. Cell Biochem Biophys 2015;71:457-64
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:4784-90
   PubMed Web of Science ®Google Scholar
• Goldberg R, Smith E, Bell S, et al. Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B. Intern Med J 2013;43:835-6
   PubMed Web of Science ®Google Scholar
• Yahav D, Gafter-Gvili A, Muchtar E, et al. Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur J Cancer 2009;45:3131-48
   PubMed Web of Science ®Google Scholar
• Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982;73:229-35
   PubMed Web of Science ®Google Scholar
• Dignani MC, Mykietiuk A, Michelet M, et al. Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation. Bone Marrow Transplant 2002;29:263-7
   PubMed Web of Science ®Google Scholar
• Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev 2009:CD006706.
   Google Scholar
• Eisen D, Essell J, Broun ER, et al. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant 2003;31:51-5
   PubMed Web of Science ®Google Scholar
• Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007;110:3071-7
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-238
   PubMed Web of Science ®Google Scholar
• Rogers JE, Cumpston A, Newton M, Craig M. Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. Transpl Infect Dis 2011;13:480-4
   PubMed Web of Science ®Google Scholar
• Kamber C, Zimmerli S, Suter-Riniker F, et al. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Bone Marrow Transplant 2015;50:573-8
   PubMed Web of Science ®Google Scholar
• Boeckh M, Kim HW, Flowers ME, et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation–a randomized double-blind placebo-controlled study. Blood 2006;107:1800-5
   PubMed Web of Science ®Google Scholar
• Selby PJ, Powles RL, Easton D, et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 1989;59:434-8
   PubMed Web of Science ®Google Scholar
• Pollack M, Heugel J, Xie H, et al. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011;17:664-73
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma 2008;8:237-40
   PubMedGoogle Scholar
• Pour L, Adam Z, Buresova L, et al. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma 2009;9:151-3
   PubMedGoogle Scholar
• Minarik J, Pika T, Bacovsky J, et al. Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. Br J Haematol 2012;159:111-13
   PubMed Web of Science ®Google Scholar
• Aoki T, Nishiyama T, Imahashi N, Kitamura K. Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study. Jpn J Clin Oncol 2011;41:876-81
   PubMed Web of Science ®Google Scholar
• Fukushima T, Sato T, Nakamura T, et al. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer Res 2012;32:5437-40
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84
   PubMed Web of Science ®Google Scholar
• Tseng HF, Tartof S, Harpaz R, et al. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis 2014;59:913-19
   PubMed Web of Science ®Google Scholar
• Naidus E, Damon L, Schwartz BS, et al. Experience with use of Zostavax((R)) in patients with hematologic malignancy and hematopoietic cell transplant recipients. Am J Hematol 2012;87:123-5
   PubMed Web of Science ®Google Scholar
• Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-7
   PubMed Web of Science ®Google Scholar
• Kim JH, Goulston C, Sanders S, et al. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation. Biol Blood Marrow Transplant 2012;18:1753-8
   PubMed Web of Science ®Google Scholar
• Marchesi F, Pimpinelli F, Dessanti ML, et al. Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study. Transpl Infect Dis 2014;16:1032-8
   PubMed Web of Science ®Google Scholar
• Marchesi F, Mengarelli A, Giannotti F, et al. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network. Transpl Infect Dis 2014;16:158-64
   PubMed Web of Science ®Google Scholar
• Rossini F, Terruzzi E, Cammarota S, et al. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. Transpl Infect Dis 2005;7:122-5
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013;369:1227-36
   PubMed Web of Science ®Google Scholar
• Teh BW, Sasadeusz JJ. Guarding the sleeping giant: hepatitis B screening and management in patients with hematological malignancy. Leuk Lymphoma 2014;55:2426-7
   PubMed Web of Science ®Google Scholar
• Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir Ther 2010;15(Suppl 3):3-14
   PubMed Web of Science ®Google Scholar
• Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1-20
   PubMedGoogle Scholar
• EASL. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85
   PubMed Web of Science ®Google Scholar
• Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010;28:3199-202
   PubMed Web of Science ®Google Scholar
• Teng CJ, Liu HT, Liu CY, et al. Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes. Clinics (Sao Paulo) 2011;66:2055-61
   PubMed Web of Science ®Google Scholar
• Lee JY, Lim SH, Lee MY, et al. Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. Liver Int 2015; Epub ahead of print
   Google Scholar
• Huang B, Li J, Zhou Z, et al. High prevalence of hepatitis B virus infection in multiple myeloma. Leuk Lymphoma 2012;53:270-4
   PubMed Web of Science ®Google Scholar
• Mya DH, Han ST, Linn YC, et al. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol 2012;23:421-6
   PubMed Web of Science ®Google Scholar
• Teh BW, Slavin MA, Szer J, Sasadeusz JJ. Hepatitis B serological changes following allogeneic bone marrow transplantation. Transpl Infect Dis 2013;15:98-103
   PubMed Web of Science ®Google Scholar
• Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-28
   PubMed Web of Science ®Google Scholar
• Uhm JE, Kim K, Lim TK, et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:463-8
   PubMed Web of Science ®Google Scholar
• Marignani M, Marzano A, Begini P, et al. Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. Leuk Lymphoma 2014;55:2564-71
   PubMed Web of Science ®Google Scholar
• Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005;54:1597-603
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-11
   PubMed Web of Science ®Google Scholar
• Yang JD, Girotra M, Restrepo A, et al. Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance. Ann Hepatol 2014;13:461-5
   PubMed Web of Science ®Google Scholar
• Gu HR, Shin DY, Choi HS, et al. HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT. Blood Res 2015;50:51-3
   Google Scholar
• Hussain S, Jhaj R, Ahsan S, et al. Bortezomib induced hepatitis B reactivation. Case Rep Med 2014;2014:964082
   PubMedGoogle Scholar
• Hirsch HH, Martino R, Ward KN, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013;56:258-66
   PubMed Web of Science ®Google Scholar
• Tramontana AR, George B, Hurt AC, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010;16:1068-75
   PubMed Web of Science ®Google Scholar
• Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4:CD008965
   Google Scholar
• Teh B, Olsen K, Black J, et al. Impact of swine influenza and quarantine measures on patients and households during the H1N1/09 pandemic. Scand J Infect Dis 2012;44:289-96
   PubMed Web of Science ®Google Scholar
• Therapeutic guidelines: antibiotic. Version 15. Therapeutic Guidelines Limited; Melbourne: 2014
   Google Scholar
• Kobold S, Luetkens T, Bartels BM, et al. Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients. Clin Dev Immunol 2012;2012:134081
   PubMed Web of Science ®Google Scholar
• Rapezzi D, Sticchi L, Racchi O, et al. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. Eur J Haematol 2003;70:225-30
   PubMed Web of Science ®Google Scholar
• Musto P, Carotenuto M. Vaccination against influenza in multiple myeloma. Br J Haematol 1997;97:505-6
   PubMed Web of Science ®Google Scholar
• Cheuk DK, Chiang AK, Lee TL, et al. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev 2011;CD006505
   PubMed Web of Science ®Google Scholar
• Hahn M, Schnitzler P, Schweiger B, et al. Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica 2015;100(7):e285-8
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Vogl DT, Luning Prak E, et al. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood 2011;117:63-71
   PubMed Web of Science ®Google Scholar
• Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant 2008;42:637-41
   PubMed Web of Science ®Google Scholar
• Machado CM, Cardoso MR, da Rocha IF, et al. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant 2005;36:897-900
   PubMed Web of Science ®Google Scholar
• Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011;117:2755-63
   PubMed Web of Science ®Google Scholar
• Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001;28:479-84
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014;371:711-22
   PubMed Web of Science ®Google Scholar
• Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the fred hutchinson cancer research center experience. Biol Blood Marrow Transplant 2001;7 Suppl:11S-5S
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood 2012;119:2738-45
   PubMed Web of Science ®Google Scholar
• Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001;98:573-8
   PubMed Web of Science ®Google Scholar
• Safety of and immune response to a cow/human parainfluenza virus vaccine (rB/HPIV3) in healthy infants, children, and adults. Available from: https://clinicaltrials.gov/ct2/show/NCT00366782
   Google Scholar
• Safety of and immune response to recombinant live-attenuated parainfluenza type 1 virus vaccine. Available from: https://clinicaltrials.gov/ct2/show/NCT00641017
   Google Scholar
• Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants. Available from: https://clinicaltrials.gov/ct2/show/NCT00308412
   Google Scholar
• An open label study to examine the effects of DAS181 administered by dry powder inhaler (DPI) or nebulized formulation in immunocompromised subjects with parainfluenza (PIV) infection. Available from: https://clinicaltrials.gov/ct2/show/NCT01924793
   Google Scholar
• A Phase II, Randomized, Double-blind, Placebo-controlled Study to examine the effects of DAS181 in immunocompromised subjects with lower respiratory tract parainfluenza infection on supplemental oxygen (DAS181-2-05). Available from: https://clinicaltrials.gov/ct2/show/NCT01644877
   Google Scholar
• Teh BW, Teng JC, Urbancic K, et al. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica 2015;100:e28-31
   PubMed Web of Science ®Google Scholar